$19.78
0.190.97%
Pre-Market: 4:13 PM EDT
15 minutes delayed
NewAmsterdam Pharma
NAMSNASDAQ
want to know what
the Bulls & Bears Say?
NewAmsterdam Pharma (NASDAQ:NAMS) Stock, Analyst Ratings, Price Targets, Forecasts
NewAmsterdam Pharma Co NV has a consensus price target of $28.29 based on the ratings of 9 analysts. The high is $37 issued by Piper Sandler on January 16, 2024. The low is $19 issued by SVB Leerink on December 20, 2022. The 3 most-recent analyst ratings were released by RBC Capital, Scotiabank, and Scotiabank on June 7, 2024, March 14, 2024, and March 13, 2024, respectively. With an average price target of $33.67 between RBC Capital, Scotiabank, and Scotiabank, there's an implied 70.21% upside for NewAmsterdam Pharma Co NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Scotiabank
Guggenheim
Piper Sandler
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for NewAmsterdam Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/07/2024 | Buy Now | 56.72% | RBC Capital | Leonid Timashev | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2024 | Buy Now | — | TD Cowen | Tyler Van Buren | — | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 76.95% | Scotiabank | George Farmer | → $35 | Initiates | Sector Outperform → Sector Outperform | Get Alert |
| 03/13/2024 | Buy Now | 76.95% | Scotiabank | George Farmer | → $35 | Initiates | → Sector Outperform | Get Alert |
| 02/29/2024 | Buy Now | 56.72% | RBC Capital | Leonid Timashev | $25 → $31 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 51.67% | Guggenheim | Debjit Chattopadhyay | → $30 | Initiates | → Buy | Get Alert |
| 01/16/2024 | Buy Now | 87.06% | Piper Sandler | Yasmeen Rahimi | → $37 | Initiates | → Overweight | Get Alert |
| 10/30/2023 | Buy Now | 26.39% | RBC Capital | Leonid Timashev | → $25 | Initiates | → Outperform | Get Alert |
| 04/03/2023 | Buy Now | 11.22% | Credit Suisse | Judah Frommer | $21 → $22 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | 6.17% | Credit Suisse | Judah Frommer | → $21 | Initiates | → Outperform | Get Alert |
| 12/20/2022 | Buy Now | -3.94% | SVB Leerink | Roanna Ruiz | → $19 | Initiates | → Outperform | Get Alert |
| 12/19/2022 | Buy Now | — | William Blair | Matthew Phipps | — | Initiates | → Outperform | Get Alert |
| 12/19/2022 | Buy Now | 21.33% | Jefferies | Dennis Ding | → $24 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for NewAmsterdam Pharma (NAMS) stock?
The latest price target for NewAmsterdam Pharma (NASDAQ:NAMS) was reported by RBC Capital on June 7, 2024. The analyst firm set a price target for $31.00 expecting NAMS to rise to within 12 months (a possible 56.72% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NewAmsterdam Pharma (NAMS)?
The latest analyst rating for NewAmsterdam Pharma (NASDAQ:NAMS) was provided by RBC Capital, and NewAmsterdam Pharma reiterated their outperform rating.
When was the last upgrade for NewAmsterdam Pharma (NAMS)?
There is no last upgrade for NewAmsterdam Pharma
When was the last downgrade for NewAmsterdam Pharma (NAMS)?
There is no last downgrade for NewAmsterdam Pharma.
When is the next analyst rating going to be posted or updated for NewAmsterdam Pharma (NAMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NewAmsterdam Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NewAmsterdam Pharma was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.
Is the Analyst Rating NewAmsterdam Pharma (NAMS) correct?
While ratings are subjective and will change, the latest NewAmsterdam Pharma (NAMS) rating was a reiterated with a price target of $31.00 to $31.00. The current price NewAmsterdam Pharma (NAMS) is trading at is $19.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.